$472.8
+1.68
(+0.36%)▲
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious medical conditions.
0.78%
Downside
Day's Volatility :1.34%
Upside
0.56%
27.69%
Downside
52 Weeks Volatility :33.04%
Upside
7.41%
Period | Vertex Pharmaceuticals Incorporated | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | -1.21% | -2.1% | 8.7% |
6 Months | 17.05% | 4.9% | 12.9% |
1 Year | 22.13% | 16.0% | 35.3% |
3 Years | 142.58% | 10.0% | 14.4% |
Market Capitalization | 122.9B |
Book Value | $57.26 |
Earnings Per Share (EPS) | -2.0 |
PEG Ratio | 1.21 |
Wall Street Target Price | 512.44 |
Profit Margin | -4.74% |
Operating Margin TTM | 35.34% |
Return On Assets TTM | 12.96% |
Return On Equity TTM | -3.24% |
Revenue TTM | 10.3B |
Revenue Per Share TTM | 40.08 |
Quarterly Revenue Growth YOY | 6.1% |
Gross Profit TTM | 5.3B |
EBITDA | 4.4B |
Diluted Eps TTM | -2.0 |
Quarterly Earnings Growth YOY | 0.56 |
EPS Estimate Current Year | 0.16 |
EPS Estimate Next Year | 18.64 |
EPS Estimate Current Quarter | 4.14 |
EPS Estimate Next Quarter | 4.07 |
What analysts predicted
Upside of 8.38%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 22.46% |
Net Income | 2.1B | ↑ 695.83% |
Net Profit Margin | 68.8% | ↑ 58.21% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.2B | ↑ 36.59% |
Net Income | 1.2B | ↓ 43.88% |
Net Profit Margin | 28.27% | ↓ 40.53% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.2B | ↑ 49.07% |
Net Income | 2.7B | ↑ 130.43% |
Net Profit Margin | 43.7% | ↑ 15.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 7.6B | ↑ 22.06% |
Net Income | 2.3B | ↓ 13.63% |
Net Profit Margin | 30.92% | ↓ 12.78% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.9B | ↑ 17.91% |
Net Income | 3.3B | ↑ 41.84% |
Net Profit Margin | 37.2% | ↑ 6.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.8B | ↑ 10.17% |
Net Income | 3.6B | ↑ 8.96% |
Net Profit Margin | 36.79% | ↓ 0.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 3.13% |
Net Income | 699.8M | ↓ 14.54% |
Net Profit Margin | 29.47% | ↓ 6.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↑ 4.99% |
Net Income | 915.7M | ↑ 30.85% |
Net Profit Margin | 36.73% | ↑ 7.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↓ 0.39% |
Net Income | 1.0B | ↑ 13.06% |
Net Profit Margin | 41.69% | ↑ 4.96% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↑ 1.38% |
Net Income | 968.8M | ↓ 6.42% |
Net Profit Margin | 38.48% | ↓ 3.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.7B | ↑ 6.73% |
Net Income | 1.1B | ↑ 13.5% |
Net Profit Margin | 40.92% | ↑ 2.44% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.6B | ↓ 1.95% |
Net Income | -3.6B | ↓ 426.81% |
Net Profit Margin | -136.4% | ↓ 177.32% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↑ 76.14% |
Total Liabilities | 1.8B | ↑ 20.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 8.3B | ↑ 33.18% |
Total Liabilities | 2.2B | ↑ 23.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.8B | ↑ 41.27% |
Total Liabilities | 3.1B | ↑ 37.25% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.4B | ↑ 14.3% |
Total Liabilities | 3.3B | ↑ 8.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 18.2B | ↑ 35.13% |
Total Liabilities | 4.2B | ↑ 27.18% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 22.7B | ↑ 25.23% |
Total Liabilities | 5.1B | ↑ 21.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 19.0B | ↑ 4.54% |
Total Liabilities | 4.5B | ↑ 7.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 20.3B | ↑ 7.25% |
Total Liabilities | 4.9B | ↑ 7.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.7B | ↑ 6.77% |
Total Liabilities | 5.2B | ↑ 6.85% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 22.7B | ↑ 4.62% |
Total Liabilities | 5.1B | ↓ 1.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 23.9B | ↑ 5.22% |
Total Liabilities | 5.4B | ↑ 4.29% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 20.1B | ↓ 15.83% |
Total Liabilities | 5.4B | ↓ 0.25% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↑ 50.34% |
Investing Cash Flow | -202.2M | ↓ 53.81% |
Financing Cash Flow | -71.2M | ↓ 204.12% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 23.54% |
Investing Cash Flow | -1.2B | ↑ 511.07% |
Financing Cash Flow | 126.8M | ↓ 278.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 107.32% |
Investing Cash Flow | 99.4M | ↓ 108.05% |
Financing Cash Flow | -505.3M | ↓ 498.57% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6B | ↓ 18.75% |
Investing Cash Flow | -340.9M | ↓ 443.0% |
Financing Cash Flow | -1.5B | ↑ 192.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.1B | ↑ 56.23% |
Investing Cash Flow | -321.1M | ↓ 5.81% |
Financing Cash Flow | -67.7M | ↓ 95.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 899.9M | ↓ 16.55% |
Investing Cash Flow | -1.8B | ↓ 1144.19% |
Financing Cash Flow | -294.7M | ↓ 833.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 26.06% |
Investing Cash Flow | -303.9M | ↓ 83.43% |
Financing Cash Flow | 17.3M | ↓ 105.87% |
Sell
Neutral
Buy
Vertex Pharmaceuticals Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | 3.47% | 17.05% | 22.13% | 142.58% | 136.25% |
Regeneron Pharmaceuticals, Inc. | -16.71% | -12.0% | 1.34% | 30.26% | 171.22% |
Biontech Se | -9.13% | 19.42% | 11.8% | -59.3% | 487.66% |
Alnylam Pharmaceuticals, Inc. | 2.21% | 81.13% | 63.87% | 47.62% | 198.57% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Insights on Vertex Pharmaceuticals Incorporated
Revenue is down for the last 2 quarters, 2.68B → 2.63B (in $), with an average decrease of 2.0% per quarter
Netprofit is down for the last 2 quarters, 1.09B → -3.59B (in $), with an average decrease of 426.8% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.7% return, outperforming this stock by 38.5%
Capital World Investors
Vanguard Group Inc
BlackRock Inc
State Street Corp
FMR Inc
Capital Research Global Investors
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Organization | Vertex Pharmaceuticals Incorporated |
Employees | 5400 |
CEO | Dr. Jeffrey Marc Leiden M.D., Ph.D. |
Industry | Health Technology |
Constellation Brands Inc.
$472.80
+0.36%
Lpl Financial Holdings Inc.
$472.80
+0.36%
Reit Vanguard Etf
$472.80
+0.36%
Citizens Financial Group, Inc.
$472.80
+0.36%
Jpmorgan Usd Emerg Markets Bond Ishares
$472.80
+0.36%
Icici Bank Ltd.
$472.80
+0.36%
Live Nation Entertainment, Inc.
$472.80
+0.36%
Cubesmart
$472.80
+0.36%
Molson Coors Beverage Co
$472.80
+0.36%